Questions
What was Geron trying to do when it was founded?
Michael West founded it in 1992 to find the molecular mechanism behind the Hayflick limit, the point where normal cells stop dividing, and build drugs around it. The idea was that switching on telomerase might reverse aging and switching it off might kill cancer.
What is the Hayflick limit and why does it matter?
Leonard Hayflick showed in 1961 that normal human cells stop dividing after about 50 doublings, contradicting the belief that cells could live forever. Telomeres, protective caps on chromosomes, shorten with each division, which is why cells stop.
Did Geron ever get a drug approved?
Yes. On June 6, 2024 the FDA approved imetelstat, sold as Rytelo (the transcript spells it Ritello), for low-risk myelodysplastic syndromes, a bone marrow cancer. The hosts call it the world's first approved telomerase inhibitor.
Why did Geron's stem cell program for spinal cord injury end?
The program was expensive, losses were approaching $700 million, and the 2008 recession had hurt funding. In November 2011 new leadership refocused the company on cancer, after five patients had been dosed.
Is Geron considered a success?
The hosts give it an A-plus for academic impact, roughly a C for financial impact, and a mediocre patient-impact score. They credit its science and persistence, but say investors saw little return.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
In 1961 cell biologist Leonard Hayflick published a paper showing that normal human cells cannot divide indefinitely, a finding later called the Hayflick limit.
“1961, a cell biologist named Leonard Hayflick publishes a paper showing that normal human cells cannot divide forever.”
0:01:15 · Alex Kesin · Hayflick limit · 1961
In 1912 Alexis Carrel, a surgeon at the Rockefeller Institute, claimed he could keep chicken heart cells alive in culture indefinitely, a belief that shaped the dogma Hayflick challenged.
“In 1912, Alexis Carell, a French surgeon at the Rockefeller Institute, a Nobel laureate and a eugenicist, claimed he could keep chicken heart cells alive in culture indefinitely.”
0:02:49 · Matthew Pech · Cell immortality dogma · 1912
Leonard Hayflick's WI-38 cell line became a standard substrate for manufacturing human viral vaccines.
“Hayflick's WI38 cells end up being the standard substrate for manufacturing human viral vaccines.”
0:06:16 · Matthew Pech · WI-38 vaccines
After Leonard Hayflick distributed WI-38 cells at cost, federal authorities confiscated his cultures and Stanford pushed him out, according to the hosts.
“The feds confiscate his cultures while he's away at a conference, and Stanford pushes him out and ends up, unfortunately, collecting unemployment.”
0:07:09 · Alex Kesin · Hayflick dispute
Congress passed the Bayh-Dole Act, which for the first time allowed researchers to profit from federally funded discoveries.
“Congress ends up passing the Bay Dole Act, which for the first time allows researchers to profit from federally funded discoveries.”
0:07:39 · Alex Kesin · Bayh-Dole Act
Michael West registered the name Geron, a Greek word meaning old man, and told the New York Times he took it from a New Testament passage about an old man being born again.
“West later told the New York Times that he took the word from a passage in the New Testament in which Jesus describes how a man who is old might be born again.”
0:10:55 · Alex Kesin · Company name
At a 1991 biotech venture conference in Redwood Shores, Michael West was promised $17 million in funding for Geron within 90 minutes of his pitch.
“Within 90 minutes, West had been promised $17 million.”
0:14:01 · Matthew Pech · Geron funding · 1991
Genentech raised $35 million in its 1980 initial public offering, which was considered an enormous amount at the time.
“Genentech, when it went public in 1980, 10 years earlier, it raised $35 million”
0:14:01 · Matthew Pech · Biotech financing · 1980
Geron formally launched in March 1992 with backing from Kleiner Perkins, Venrock and Domain Associates.
“Geron formally launches a year later in March of 1992 with backing from Cream of the Crop Venture Capital, Kleiner Perkins, Venrock, and Domain Associates.”
0:15:16 · Matthew Pech · Geron founding · 1992
On December 23, 1994, Geron scientists published a paper showing telomerase activity in most cancer cell lines, introducing the TRAP assay and becoming a highly cited cancer biology paper.
“On December 23, 1994, Geron scientists published what will become one of the most cited papers in cancer biology.”
0:25:47 · Matthew Pech · Telomerase paper · 1994
In 1995 Congress passed the Dickey-Wicker Amendment, signed by President Bill Clinton, which barred federal funding for research in which human embryos are created or destroyed.
“In 1995, they passed the Dickey-Wicker Amendment, attached to the annual appropriations bill for the Department of Health and Human Services, and Clinton signed it into law.”
0:29:35 · Alex Kesin · Dickey-Wicker Amendment · 1995
Geron's 1996 initial public offering sold 2 million shares at $8 each, raising $16 million, below its hoped-for price range of $11 to $12.
“They end up selling 2 million shares at $8 apiece, raising $16 million in gross proceeds.”
0:31:59 · Matthew Pech · Geron IPO · 1996
When the Geron paper on extending cell lifespan with telomerase appeared in January 1998, the company's stock nearly quadrupled in a single day.
“When that paper comes out in January of 1998, Geron's stock nearly quadruples in a single day on leaked rumors.”
0:41:03 · Alex Kesin · Geron stock · 1998
Michael West left Geron in February 1998 after the board kept the stem cell work in-house under Thomas Okarma rather than spinning it into a subsidiary.
“This is the final straw for West. feeling the betrayal he leaves in February of 1998.”
0:45:26 · Matthew Pech · West departure · 1998
On August 9, 2001, President George W. Bush announced that federal funding would be limited to embryonic stem cell lines that already existed.
“On August 9th, 2001, President Bush delivers an 11-minute televised address from his Crawford, Texas ranch.”
0:54:37 · Alex Kesin · Stem cell policy · 2001
On October 8, 2010, Timothy J. Atchison became the first person to receive a human embryonic stem cell-derived therapy, at the Shepherd Center in Atlanta.
“On October 8th of 2010, Timothy J. Atchison of Alabama becomes the first person in history to receive human embryonic stem cell-derived therapy.”
1:15:39 · Alex Kesin · First stem cell trial · 2010
On November 14, 2011, Geron announced by email that it would focus only on oncology and stop funding its stem cell programs.
“On November 14th of 2011, not even a year after the initiation of the stem cell study, Anna Krasowska from Geron's Investor and Media Relations Department sends a devastating email.”
1:19:22 · Alex Kesin · Stem cell shutdown · 2011
In January 2013 BioTime, led by Michael West, acquired Geron's stem cell portfolio.
“In January 2013, which is a couple of years after the program is officially dead, a company by the name of Biotime swoops in and entirely acquires Geron's stem cell portfolio”
1:25:51 · Alex Kesin · BioTime acquisition · 2013
On March 12, 2014, the FDA placed a full clinical hold on all imetelstat trials over liver toxicity, and Geron's stock fell more than 60 percent that day.
“On March 12, 2014, the FDA places a full clinical hold on all Amelstat trials.”
1:42:48 · Matthew Pech · FDA clinical hold · 2014
In November 2014 Geron announced a Janssen Biotech deal for imetelstat worth $35 million up front and up to $900 million in milestones.
“$35 million up front, up to $900 million in milestones.”
1:43:26 · Matthew Pech · Janssen deal · 2014
On September 27, 2018, Janssen terminated its imetelstat deal and returned the rights to Geron, citing portfolio prioritization.
“On September 27, 2018, they terminate the deal and lean the rights back to Geron.”
1:44:38 · Matthew Pech · Janssen termination · 2018
On March 14, 2024, the FDA's Oncology Drugs Advisory Committee voted 12 to 2 that imetelstat's benefits outweigh its risks.
“On March 14, 2024, FDA's Oncology Drugs Advisory Committee votes 12 to 2 that the benefits of the metal stat outweigh its risk.”
1:49:53 · Matthew Pech · FDA advisory vote · 2024
On June 6, 2024, the FDA approved imetelstat for low-risk myelodysplastic syndromes, making it the first approved telomerase inhibitor.
“And on June 6, 2024, the FDA ultimately approves metal stat, now called Rotello, for its use in low-risk MDS.”
1:50:28 · Matthew Pech · FDA approval · 2024
In November 2024 Geron sold Royalty Pharma tiered royalties on U.S. sales of its approved drug in exchange for $125 million up front.
“Geron gets $125 million up front in exchange for tiered royalty payments on U.S. Ritello sales.”
1:47:32 · Alex Kesin · Royalty financing · 2024